Which is better? The differences between carrier-added Lu-177 and non-carrier-added Lu-177

Isotope purity is the foundation for safer, more effective treatment.

Behind Every Dose: A Choice in Performance

Cancer therapies such as Pluvicto™ and Lutathera™ depend on Lutetium-177. But what you may not realize is that Lu-177 itself comes in two different forms: carrier-added (c.a.) and non-carrier-added (n.c.a.).

That means each dose contains either Lu-177 with non-therapeutic isotopes or Lu-177 in ultra-pure form. The distinction is a critical one because it affects 1) how well the tumor is treated and 2) how effectively healthy tissue is protected.

This matters deeply to patients. For those with neuroendocrine tumors or metastatic prostate cancer, these therapies often represent hope after other treatments have failed. Each infusion session requires careful preparation and monitoring, and the quality of the Lu-177 used directly influences how their body responds – both in fighting cancer and in managing side effects.

Ilumira™: ≥99.9% Pure Lu-177. Designed for Therapy Success.

To meet rising demand for this critical therapy isotope, SHINE produces Ilumira n.c.a. Lu-177 at our U.S. facility in Janesville, Wisconsin.

• Manufactured under cGMP standards and supported by an FDA Drug Master File

• Built on a secure, U.S.-based supply chain

• Demonstrated strong uptake in tumor sites by clinical partners administering in clinical settings
  

When Quality Defines Better Therapy

Isotope purity determines how therapies perform—and patients experience the results. n.c.a. Lu-177 enables cancer therapy to be more predictable and effective. Contact us to see how Ilumira can support your patients and programs.

‍